Print

RESEARCH PROGRAMS

The Ipsen group’s research programs are focused on developing new formulations and studying the mechanism by which botulinum toxin acts. In the field of neurodegenerative illnesses, the Group has synthesized several original families of chimeric molecules (molecules capable of exerting multiple pharmacological activities). Some of these molecules are intended to protect the mitochondria (intracellular organelles responsible for energy function), the dysfunction of which plays a major part in neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.

DEVELOPMENT PROGRAMS

BOTULINUM TOXIN TYPE A

Medical use

In April 2009, US regulatory authorities approved an application for marketing authorization for the biological product (Biologics License Application or BLA) for Dysport^® (abobotulinumtoxin A) for the treatment of cervical dystonia to reduce the severity of abnormal head position and cervical pain. Ipsen markets Dysport^® in the US in its therapeutic indication (cervical dystonia). Moreover, the unique name “abobotulinumtoxin A” differentiates Dysport^® from other botulinum toxin-based products on the market.

Esthetic medicine

Dysport^®

In April 2009, US regulatory authorities also approved an application for marketing authorization for the biological product for Dysport^® (abobotulinumtoxin A) for its esthetic indication – the temporary correction of moderate to severe frown lines in adults aged under 65. Medicis markets Dysport^® in the US in this indication.

Azzalure^®

The Group has granted Galderma the exclusive rights to develop, promote and distribute its botulinum toxin type product for esthetic indications in Europe and certain other territories. Galderma markets this product under its own Azzalure^® brand.

On February 2, 2009, Azzalure^® was granted a collective green light by health authorities in 15 European countries (via a decentralized procedure) to proceed with the issuance of national marketing authorizations. The evaluation was based on clinical studies performed on more than 2,600 patients, accrediting the product’s tolerance profile and effectiveness. At end 2009, this treatment was marketed in seven European countries.